TLR2 Heterodimerization Inhibitors for Selective Anti-Inflammatory Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for inflammatory diseases and neurological disorders associated with TLR2 heterodimerization lack specificity and often interfere with both pathological and non-pathological inflammatory responses, leading to undesirable side effects.
Innovation Solution
Development of compounds that act as potent and selective antagonists of TLR2, specifically designed to inhibit TLR2 heterodimerization, thereby modulating inflammatory responses without affecting non-pathological signaling pathways.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for TLR2-associated inflammatory diseases are used, then inflammatory responses are suppressed, but non-pathological immune responses are also interfered with causing side effects
Solution Approach 1:
The invention segments the TLR2 signaling pathway by developing compounds that specifically target TLR2 heterodimerization (TLR2-TLR1 or TLR2-TLR6) while leaving other TLR pathways intact. This selective inhibition of TLR2 heterodimers allows suppression of pathological inflammatory responses without interfering with non-pathological immune responses mediated by other TLRs, thereby resolving the contradiction between treatment effectiveness and selectivity.
2Adaptability or versatility
If broad-spectrum TLR inhibitors are used, then multiple inflammatory pathways are blocked, but specificity for pathological pathways is lost
Solution Approach 1:
The invention applies local quality by designing compounds with specific molecular structures (Formula I and Formula II) that selectively bind to and inhibit TLR2 heterodimerization interfaces. These compounds exhibit localized specificity for TLR2-TLR1 and TLR2-TLR6 heterodimers, allowing broad anti-inflammatory effects through TLR2 pathway blockade while preserving the function of other TLRs and non-pathological immune signaling pathways.
Data Source
AI summary
The present disclosure relates to compounds, pharmaceutical compositions comprising such compounds, and use of such compounds in methods of treatment or in medicaments for treatment of inflammatory diseases and certain neurological disorders that are related to inflammatory signaling processes, including but not limited to misfolded proteins.